NICE Appraisal Changes: Confusing, Contradictory & Questionable
New NICE and NHS England appraisal rules regarding timelines and price thresholds could fast-track new cost-effective drugs but then delay them from reaching patients for up to three years. The new regulations, which will come into force in April, have raised a lot of questions around methodology and impact outside of England.
You may also be interested in...
The ABPI decides not to appeal after the High Court rejected what NHS England called 'flawed legal manoeuvres' which the judge said would ‘produce an absurd result.’
The multi-faceted UK life sciences industry has been told to develop more connective tissue and encourage a more activist government industrial strategy to help it thrive after the country departs the European Union.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.